Core Insights - AstraZeneca and Amgen's TEZSPIRE® has received approval in the US for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and pediatric patients aged 12 years and older [1] - TEZSPIRE is the first and only biologic targeting thymic stromal lymphopoietin (TSLP) approved for CRSwNP, indicating a significant advancement in treatment options for this condition [1] Company Summary - The approval by the US Food and Drug Administration (FDA) marks a milestone for AstraZeneca and Amgen in expanding their product offerings in the field of chronic inflammatory diseases [1] - TEZSPIRE's unique mechanism of action targeting TSLP positions it as a pioneering treatment in the biologics market for CRSwNP [1]